Advocacy intelligence hub — real-time data for patient organizations
NovoSeven: FDA approved
Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
NovoSeven
Novo Nordisk, Inc.
NovoSeven
(Coagulation factor VIIa (recombinant))Orphan drugNovo Nordisk, Inc.
12.1 Mechanism of Action The active ingredient in SEVENFACT is a recombinant analog of human Factor VIIa, a vitamin K-dependent coagulation factor. In...
Browse all Bleeding disorder in hemophilia A carriers news →
View all Bleeding disorder in hemophilia A carriers specialists →